17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Global Perspectives on Immunization During Pregnancy and Priorities for Future Research and Development: An International Consensus Statement

      review-article
      1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 2 , 2 , 11 , 12 , 13 , 14 , 15 , 16 , 15 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 10 , 28 , 29 , 30 , 15 , 31 , 32 , *
      Frontiers in Immunology
      Frontiers Media S.A.
      group B Streptococcus vaccines, influenza, maternal immunization, pertussis, pregnant women, respiratory syncytial virus, tetanus

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Immunization during pregnancy has been recommended in an increasing number of countries. The aim of this strategy is to protect pregnant women and infants from severe infectious disease, morbidity and mortality and is currently limited to tetanus, inactivated influenza, and pertussis-containing vaccines. There have been recent advancements in the development of vaccines designed primarily for use in pregnant women (respiratory syncytial virus and group B Streptococcus vaccines). Although there is increasing evidence to support vaccination in pregnancy, important gaps in knowledge still exist and need to be addressed by future studies. This collaborative consensus paper provides a review of the current literature on immunization during pregnancy and highlights the gaps in knowledge and a consensus of priorities for future research initiatives, in order to optimize protection for both the mother and the infant.

          Related collections

          Most cited references187

          • Record: found
          • Abstract: found
          • Article: not found

          Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon?

          Pregnant females are susceptible to intracellular pathogens and are biased towards humoral rather than cell-mediated immunity. Since TH1 cytokines compromise pregnancy and TH2 cytokines are produced at the maternal-fetal interface, we hypothesize that these TH2 cytokines inhibit TH1 responses, improving fetal survival but impairing responses against some pathogens.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Pregnancy and infection.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Respiratory Syncytial Virus—A Comprehensive Review

              Respiratory syncytial virus (RSV) is amongst the most important pathogenic infections of childhood and is associated with significant morbidity and mortality. Although there have been extensive studies of epidemiology, clinical manifestations, diagnostic techniques, animal models and the immunobiology of infection, there is not yet a convincing and safe vaccine available. The major histopathologic characteristics of RSV infection are acute bronchiolitis, mucosal and submucosal edema, and luminal occlusion by cellular debris of sloughed epithelial cells mixed with macrophages, strands of fibrin, and some mucin. There is a single RSV serotype with two major antigenic subgroups, A and B. Strains of both subtypes often co-circulate, but usually one subtype predominates. In temperate climates, RSV infections reflect a distinct seasonality with onset in late fall or early winter. It is believed that most children will experience at least one RSV infection by the age of 2 years. There are several key animal models of RSV. These include a model in mice and, more importantly, a bovine model; the latter reflects distinct similarity to the human disease. Importantly, the prevalence of asthma is significantly higher amongst children who are hospitalized with RSV in infancy or early childhood. However, there have been only limited investigations of candidate genes that have the potential to explain this increase in susceptibility. An atopic predisposition appears to predispose to subsequent development of asthma and it is likely that subsequent development of asthma is secondary to the pathogenic inflammatory response involving cytokines, chemokines and their cognate receptors. Numerous approaches to the development of RSV vaccines are being evaluated, as are the use of newer antiviral agents to mitigate disease. There is also significant attention being placed on the potential impact of co-infection and defining the natural history of RSV. Clearly, more research is required to define the relationships between RSV bronchiolitis, other viral induced inflammatory responses, and asthma.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Immunol
                Front Immunol
                Front. Immunol.
                Frontiers in Immunology
                Frontiers Media S.A.
                1664-3224
                24 June 2020
                2020
                : 11
                : 1282
                Affiliations
                [1] 1Department of Pediatrics, University of British Columbia , Vancouver, BC, Canada
                [2] 2Faculty of Medicine and Health Sciences, Centre for the Evaluation of Vaccination, Vaccine and Infectious Diseases Institute, University of Antwerp , Antwerp, Belgium
                [3] 3Division of Pediatric Infectious Diseases, Department of Pediatrics, Vanderbilt University School of Medicine , Nashville, TN, United States
                [4] 4Department of Internal Medicine (Infectious Diseases), Department of Epidemiology of Microbial Diseases, Yale School of Medicine, Yale School of Public Health , New Haven, CT, United States
                [5] 5Department of Pediatrics, Seattle Children's Research Institute, University of Washington , Seattle, WA, United States
                [6] 6Faculty of Health Sciences, School of Medicine, University of Tasmania , Launceston, TAS, Australia
                [7] 7School of Health and Biomedical Science, RMIT University , Melbourne, VIC, Australia
                [8] 8Department of Immunology and Pathology, Monash University , Melbourne, VIC, Australia
                [9] 9Oxford Vaccine Group, Department of Paediatrics, University of Oxford , Oxford, United Kingdom
                [10] 10Immunisation and Countermeasures Division, National Infection Service, Public Health England , London, United Kingdom
                [11] 11Third Department of Pediatrics, University Hospital ATTIKON, National and Kapodistrian University of Athens , Athens, Greece
                [12] 12Université de Paris, Inserm, CIC 1417, F-CRIN I REIVAC, Assistance Publique-Hôpitaux de Paris , Paris, France
                [13] 13The Faculty of Health Sciences, Ben-Gurion University of the Negev , Beer-Sheva, Israel
                [14] 14Preventive Medicine and Epidemiology Department, Hospital Universitario Vall d'Hebron , Barcelona, Spain
                [15] 15Dipartimento Scienze della Salute della Donna e del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario “A. Gemelli” IRCCS-Università Cattolica del Sacro Cuore , Rome, Italy
                [16] 16Department of Medicine and Surgery, Obstetrics and Gynaecology Unit, University of Parma , Parma, Italy
                [17] 17Microbiology and Mycology Program, Faculty of Medicine, Institute of Biomedical Sciences and Associate Researcher, Millennium Institute of Immunology and Immunotherapy, University of Chile , Santiago, Chile
                [18] 18Pediatric Infectious Diseases, University of Basel Children's Hospital , Basel, Switzerland
                [19] 19Division of Pediatric Infectious Diseases, Department of Pediatrics, Northwestern University Feinberg School of Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago , Chicago, IL, United States
                [20] 20Department of Pediatrics, College of Medicine and Health Sciences, United Arab Emirates University , Al Ain, United Arab Emirates
                [21] 21Department of Pediatrics, Santa Casa de São Paulo School of Medical Sciences , São Paulo, Brazil
                [22] 22Unit of Obstetrics and Gynecology, Buzzi Hospital - ASST Fatebenefratelli Sacco, University of Milan , Milan, Italy
                [23] 23Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University , Bangkok, Thailand
                [24] 24Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, Faculty of Health Sciences, University of the Witwatersrand , Johannesburg, South Africa
                [25] 25Medical Research Council: Respiratory and Meningeal Pathogens Research Unit, Faculty of Health Sciences, University of the Witwatersrand , Johannesburg, South Africa
                [26] 26Department of Obstetrics and Gynaecology, Monash University , Melbourne, VIC, Australia
                [27] 27School of Medicine Hradec Kralove, Institute of Social Medicine, Charles University Prague , Prague, Czechia
                [28] 28Translational Pediatrics and Infectious Diseases, Pediatrics Department, Hospital Clínico Universitario de Santiago de Compostela, University of Santiago , Santiago de Compostela, Spain
                [29] 29Immunization Action Coalition , St. Paul, MN, United States
                [30] 30Infectious Diseases and Vaccinology Division, Health Sciences Post Graduation Program, University of Caxias Do Sul , Caxias Do Sul, Brazil
                [31] 31Università degli Studi di Milano , Milan, Italy
                [32] 32Department of Medicine and Surgery, Pediatric Clinic, Pietro Barilla Children's Hospital, University of Parma , Parma, Italy
                Author notes

                Edited by: Fabio Bagnoli, GlaxoSmithKline, Italy

                Reviewed by: Thorsten Demberg, Marker Therapeutics, United States; Selidji Todagbe Agnandji, Centre de Recherche Médicales de Lambaréné, Gabon

                *Correspondence: Susanna Esposito susannamariaroberta.esposito@ 123456unipr.it

                This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology

                Article
                10.3389/fimmu.2020.01282
                7326941
                32670282
                a80c9a84-5573-4b9f-98ec-00c4aa412c0d
                Copyright © 2020 Abu-Raya, Maertens, Edwards, Omer, Englund, Flanagan, Snape, Amirthalingam, Leuridan, Damme, Papaevangelou, Launay, Dagan, Campins, Cavaliere, Frusca, Guidi, O'Ryan, Heininger, Tan, Alsuwaidi, Safadi, Vilca, Wanlapakorn, Madhi, Giles, Prymula, Ladhani, Martinón-Torres, Tan, Michelin, Scambia, Principi and Esposito.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 12 March 2020
                : 20 May 2020
                Page count
                Figures: 2, Tables: 11, Equations: 0, References: 256, Pages: 24, Words: 20991
                Categories
                Immunology
                Review

                Immunology
                group b streptococcus vaccines,influenza,maternal immunization,pertussis,pregnant women,respiratory syncytial virus,tetanus

                Comments

                Comment on this article